In a report released today, Miki Sogi from Bernstein maintained a Buy rating on Astellas Pharma (ALPMF – Research Report), with a price target ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Karen Lewis (JO:LEWJ), the Chief People Officer at Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a $3.75 billion market cap ...

Pascal Deschatelets, the Chief Scientific Officer of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), recently executed a stock transaction involving the sale of company shares. According to a filing with ...

Analog Devices, Inc. (NASDAQ: ADI) today announced the appointment of Andrea F. Wainer, a seasoned healthcare executive, to ...

Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

Diabetes and weight management drugs dominated game-day NFL advertising during the regular season, with TV outcomes company ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Astellas Pharma has agreed its largest-ever acquisition, buying US biotech Iveric Bio in a deal that continues to build its presence in the ophthalmology sector, The $40-per-share offer values ...

And Astellas UK and Astellas Pharma Europe were also judged to have failed to update and provide complete prescribing information for “a number” of medicines. The PMCPA said this raised ...